Biotech Values

[DewDiligence]

Lovenox for all the talk about how complicated a compound it is should actually be very cheap to produce.

Compared to a typical glycoprotein drug, Lovenox production ought to be dirt cheap, but I suspect that many investors do not understand this. Part of the blame can probably be placed on the spate of recent blogs in which Lovenox is referred to as a protein (e.g. #msg-53209453).